Talanx AG : Back on price levels to sell
Entry price | Target | Stop-loss | Potential |
---|
€32.63 |
€30.8 |
€32.9 |
+5.61% |
---|
Talanx AG shares can be expected to top out below the medium term resistance at 32.56 EUR. The timing appears attractive to take advantage of a correction below this level.
Summary● The company usually posts poor financials for mid or long term investments.
Strengths● There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
● Historically, the company has been releasing figures that are above expectations.
● Its low valuation, with P/E ratio at 10.04 and 10.22 for the ongoing fiscal year and 2017 respectively, makes the stock pretty attractive with regard to earnings multiples.
● The company is one of the best yield companies with high dividend expectations.
● The tendency within the weekly time frame is positive above the technical support level at 29 EUR
Weaknesses● The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
● The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.